Study Finds No Advantage of Biomarker-Based Risk Scores in Personalizing Atrial Fibrillation Treatment
A recent study reveals that biomarker-based risk scores do not improve outcomes in personalized atrial fibrillation care compared to traditional guidelines, highlighting the need for further research in treatment customization.
Recent research presented at ESC Congress 2025 has concluded that using biomarker-based risk scores to tailor treatment strategies in patients with atrial fibrillation (AF) does not lead to improved clinical outcomes compared to standard guideline-based care. The study, a large registry-based randomized trial conducted across 39 Swedish sites, investigated whether incorporating biomarker scores like ABC-AF-stroke and ABC-AF-bleeding into treatment decisions would reduce the incidence of stroke and death.
Patients eligible for the trial included adults diagnosed with AF, regardless of whether they were on oral anticoagulant (OAC) therapy. Participants were randomized into two groups: a treatment arm guided by individual risk scores and recommendations, and a control group managed under usual clinical practice without biomarker data. Although the intervention successfully increased OAC use broadly, the primary outcome—composite of stroke or death—occurred at similar rates in both groups, around 3.2/100 patient-years.
The trial also found no significant differences in the rates of stroke, death, or major bleeding between the two arms over a median follow-up of 2.6 years. Despite the promising validation of these biomarker scores in previous studies, the results suggest that their implementation for personalized treatment did not provide additional benefit in this population. Notably, the trial was prematurely terminated due to safety concerns, and the event rates were lower than expected, leading to an underpowered study.
Lead researcher Professor Jonas Oldgren emphasized that further prospective testing is essential before integrating new risk stratification tools into routine AF management. Overall, this study underscores the importance of rigorous validation of precision medicine approaches and suggests that current standard care remains effective for stroke prevention in AF patients.
Source: https://medicalxpress.com/news/2025-09-benefit-biomarker-based-scores-personalize.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
CDC Considers Ban on Thimerosal in Vaccines: Key Points You Should Know
Learn about the CDC's move to ban thimerosal in vaccines, its safety profile, and what this means for vaccine availability and public health.
FDA Collaborates with Border Authorities to Intercept Large Quantity of Illegal E-Cigarettes
The FDA and U.S. Customs teamed up in a major operation to seize nearly 2 million illegal e-cigarettes imported from China, valued at over $33 million, highlighting ongoing efforts to combat unregulated vaping products entering the U.S. market.
Exploring Low-Dose Naltrexone as a Potential Treatment for Long COVID
Research from Griffith University suggests that low-dose naltrexone, a drug used for opioid addiction, may be an effective treatment for Long COVID by restoring cellular function and improving symptoms.
The Role of Fetal Autopsies in Preventing Stillbirths and Addressing Society’s Blame
Fetal autopsies are essential for understanding and preventing stillbirths but are underutilized and wrongly used to blame mothers, especially in criminal cases. Improving access and expertise is key to better outcomes.